WO1996018733A3 - Ribozyme-mediated inactivation of leukemia-associated rna - Google Patents
Ribozyme-mediated inactivation of leukemia-associated rna Download PDFInfo
- Publication number
- WO1996018733A3 WO1996018733A3 PCT/US1995/016451 US9516451W WO9618733A3 WO 1996018733 A3 WO1996018733 A3 WO 1996018733A3 US 9516451 W US9516451 W US 9516451W WO 9618733 A3 WO9618733 A3 WO 9618733A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- associated rna
- leukemia
- rna
- ribozyme
- mediated inactivation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3527—Other alkyl chain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
RNA molecules, including ribozymes, external guide sequences for RNAse P, and antisense oligonucleotides have been constructed which promote ribozyme cleavage of, or block transcription of, respectively, specific cancer-associated RNA, for example, acute promyeloleukocytic leukemia-associated RNA, follicular lymphoma-associated RNA and chronic myelocytic leukemia-associated RNA. Methods of producing and using such RNA molecules are also described.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU49619/96A AU4961996A (en) | 1994-12-14 | 1995-12-14 | Ribozyme-mediated inactivation of leukemia-associated rna |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35495694A | 1994-12-14 | 1994-12-14 | |
US354,956 | 1994-12-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996018733A2 WO1996018733A2 (en) | 1996-06-20 |
WO1996018733A3 true WO1996018733A3 (en) | 1996-12-12 |
Family
ID=23395618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/016451 WO1996018733A2 (en) | 1994-12-14 | 1995-12-14 | Ribozyme-mediated inactivation of leukemia-associated rna |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4961996A (en) |
WO (1) | WO1996018733A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869248A (en) * | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
US5683873A (en) * | 1995-01-13 | 1997-11-04 | Innovir Laboratories, Inc. | EGS-mediated inactivation of target RNA |
US6057153A (en) * | 1995-01-13 | 2000-05-02 | Yale University | Stabilized external guide sequences |
US20020081733A1 (en) * | 1995-11-14 | 2002-06-27 | Catherine M. Verfaillie | Method to prepare drug-resistant, non-malignant hematopoietic cells |
US5877162A (en) * | 1996-03-14 | 1999-03-02 | Innovir Laboratories, Inc. | Short external guide sequences |
WO1998006837A1 (en) * | 1996-08-16 | 1998-02-19 | Yale University | Phenotypic conversion of drug-resistant bacteria to drug-sensitivity |
AU737190B2 (en) * | 1996-12-06 | 2001-08-09 | Niels Pallisgaard | Detection of chromosomal abnormalities |
US6013447A (en) * | 1997-11-21 | 2000-01-11 | Innovir Laboratories, Inc. | Random intracellular method for obtaining optimally active nucleic acid molecules |
CA2310510C (en) * | 1997-11-21 | 2007-04-17 | Yale University | Method for identifying and inhibiting functional nucleic acid molecules in cells |
US6248525B1 (en) | 1998-03-30 | 2001-06-19 | Yale University | Method for identifying essential or functional genes |
WO2001004304A1 (en) | 1999-07-07 | 2001-01-18 | Zymogenetics, Inc. | Human cytokine receptor |
US20030153083A1 (en) | 2000-01-31 | 2003-08-14 | Alexei Shir | Selective killing of cells by activation of double-stranded rna dependent protein kniase-pkr |
FR2832154B1 (en) | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | OLIGONUCLEOTIDES INHIBITORS AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE |
EP1356820A1 (en) * | 2002-04-26 | 2003-10-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | DNA vaccine combined with an inducer of tumor cell apoptosis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993023057A1 (en) * | 1992-05-14 | 1993-11-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting cancer development |
WO1995023225A2 (en) * | 1994-02-23 | 1995-08-31 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting the expression of disease related genes |
-
1995
- 1995-12-14 AU AU49619/96A patent/AU4961996A/en not_active Abandoned
- 1995-12-14 WO PCT/US1995/016451 patent/WO1996018733A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993023057A1 (en) * | 1992-05-14 | 1993-11-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting cancer development |
WO1995023225A2 (en) * | 1994-02-23 | 1995-08-31 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting the expression of disease related genes |
Non-Patent Citations (11)
Title |
---|
37TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, SEATTLE, WASHINGTON, USA, DECEMBER 1-5, 1995. * |
85TH ANN.MEET. AM.ASSOC. CANCER RES.; SAN FRANCISCO, 10 April 1994 (1994-04-10) - 13 April 1994 (1994-04-13) * |
DE TH, H. ET AL.: "The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promylocytic leukemia encods a functionally altered RAR", CELL, vol. 66, 23 August 1991 (1991-08-23), NA US, pages 675 - 684, XP002008608 * |
KEYSTONE SYMPOSIUM ON RIBOZYMES: BASIC SCIENCE AND THERAPEUTIC APPLICATIONS, BRECKENRIDGE, COLORADO, USA, 15 January 1995 (1995-01-15) - 21 January 1995 (1995-01-21) * |
NASON-BURCHENAL, K. ET AL.: "Over-expression of ribozymes cleaving PML-RAR-alpha in vitro is cytotoxic to acute promyelocytic leukemia cells in vivo.", BLOOD 86 (10 SUPPL. 1). PAGE 263A, ABSTRACT 1037, 15 November 1995 (1995-11-15), XP002008611 * |
NORDSTROM, J. ET AL.: "External guide sequences that direct human ribonuclease P to cleave the fusion junction of the PML-RAR-alpha RNA of acute promyelocytic leukemia.", JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT 0 (19A).1995. PAGE 223, ABSTRACT A6-317, XP002008610 * |
PACE, U. ET AL.: "A ribozyme which discriminates in vitro between PML/RAR alpha, the t(15;17)-associated fusion RNA of acute promyelocytic leukemia, and PML and RAR alpha, the transcripts from the nonrearranged alleles.", CANCER RESEARCH, (1994 DEC 15) 54 (24) 6365-9., XP002008609 * |
PACE, U. ET AL.: "A ribozyme which discriminates in vitro between the acute promyelocytic leukemia t(15;17) fusion RNA, PML/RAR alpha, and the normal transcripts from the non-rearranged alleles.", PROC ANNU MEET AM ASSOC CANCER RES, VOL. 35, PAGE 206, ABSTRACT #1227, March 1994 (1994-03-01), XP002008607 * |
PAOLELLA, G. ET AL.: "NUCLEASE RESISTANT RIBOZYMES WITH HIGH CATALYTIC ACTIVITY", EMBO JOURNAL, vol. 11, no. 5, 1 May 1992 (1992-05-01), pages 1913 - 1919, XP000268586 * |
ROSSI, J. ET AL.: "RNA ENZYMES (RIBOZYMES) AS ANTIVIRAL THERAPEUTIC AGENTS", TRENDS IN BIOTECHNOLOGY, vol. 8, no. 7, 1 July 1990 (1990-07-01), pages 179 - 183, XP000133090 * |
SYMONS, R. H.: "RIBOZYMES", CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 4, no. 3, 1 June 1994 (1994-06-01), pages 322 - 330, XP000523747 * |
Also Published As
Publication number | Publication date |
---|---|
WO1996018733A2 (en) | 1996-06-20 |
AU4961996A (en) | 1996-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996018733A3 (en) | Ribozyme-mediated inactivation of leukemia-associated rna | |
WO2001025488A3 (en) | Method for enrichment of natural antisense messenger rna | |
FI955428A (en) | Antisense oligonucleotides that resist abnormal entanglement and methods for their use | |
US5246921A (en) | Method for treating leukemias | |
WO1996018736A3 (en) | Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses | |
WO2003046173A1 (en) | siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME | |
US5646031A (en) | SArMV and sCYMVI hairpin ribozymes | |
HK1110631A1 (en) | Rna interference mediated by 21 and 22nt rnas | |
DE60037938D1 (en) | ANTISENSE THERAPY FOR TRPM-2 | |
AU2003293035A1 (en) | Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) | |
WO2000060115A3 (en) | Method for identifying accessible binding sites on rna | |
ATE342969T1 (en) | RIBOZYMES THAT ARE CAPABLE OF INHIBITING THE EXPRESSION OF THE CCR5 RECEPTOR | |
WO1996021731A3 (en) | Stabilized external guide sequences | |
AU4882296A (en) | DNA molecules, preparation and use in gene therapy | |
WO1996019568A3 (en) | Stabilized ribozyme analogs | |
EP1007655A4 (en) | Rnase l activators and antisense oligonucleotides effective to treat rsv infections | |
AU637354B2 (en) | Genetic units for inhibiting the function of rna | |
WO2003056022A3 (en) | Method for producing a transgenic organism using a lentiviral expression vector such as eiav | |
IL161664A0 (en) | METHOD FOR THE IN VITRO SYNTHESIS OF SHORT DOUBLE STRANDED RNAs | |
WO2003046186A1 (en) | siRNA EXPRESSION SYSTEM AND METHOD FOR PRODUCING FUNCTIONAL GENE KNOCK-DOWN CELLS USING THE SYSTEM | |
AU4595399A (en) | Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues | |
CA2086105A1 (en) | Method for treating leukemias | |
Kumar et al. | Point and compensation mutations to evaluate essential stem structures of genomic HDV ribozyme | |
PT2360253E (en) | Methods of producing knockdown cells or organisms by means of rna sequence-specific mediators of rna interference and uses thereof. | |
DE69733948D1 (en) | IN VIVO MANUFACTURE OF REPLICATIVES MOLECULES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |